Literature DB >> 24426199

Efficacy of Tumor Necrosis Factor and Interleukin-10 Analysis in the Follow-up of Nonalcoholic Fatty Liver Disease Progression.

Walid E Zahran1, Kholoud A Salah El-Dien1, Philip G Kamel1, Ahmed Shawky El-Sawaby2.   

Abstract

Tumor necrosis factor (TNF-α) is a cytokine involved in systemic inflammation during acute phase reactions. The current study was designed to investigate the levels of pro-inflammatory cytokine (TNF-α) along with the anti-inflammatory cytokine (IL-10) during progression of non-alcoholic fatty liver disease (NAFLD) from simple steatosis to non-alcoholic steatohepatitis (NASH) and fibrosis in diabetic patients, and correlate the levels of cytokines with the progression of NAFLD. Fifty-two diabetic patients compared to 18 healthy controls were participated in this study. Based on clinical diagnosis, patients were divided into three groups: simple steatosis, NASH and fibrosis. Serum liver function tests, fasting blood glucose, bilirubin, ALT, AST, TNF-α, IL-10 and lipid profile were measured. TNF-α levels were significantly higher in NAFLD patients compared to control subjects with a significant positive correlation with body mass index and fasting blood glucose (FBG) but with negative correlation with IL-10. Serum IL-10 levels were significantly lower in NAFLD patients compared with controls. A positive correlation between IL-10 and HDL-C with concomitant negative correlation between IL-10 and FBG and triacylglycerides was found. Cytokine analyses showed that there was a prominent imbalance between TNF-α and IL-10 in patients with NAFLD, and this imbalance increase by increasing the progression of NAFLD especially in obese diabetic patients. TNF-α and IL-10 could be used in diagnosis and follow-up of NAFLD stages in a way to avoid liver biopsies in greater proportion of patients.

Entities:  

Keywords:  Diagnosis; Interleukin-10; Non-alcoholic fatty liver disease; Progression; Steatohepatitis; Tumor necrosis factor-alpha

Year:  2012        PMID: 24426199      PMCID: PMC3613495          DOI: 10.1007/s12291-012-0236-5

Source DB:  PubMed          Journal:  Indian J Clin Biochem        ISSN: 0970-1915


  38 in total

Review 1.  The role of oxidative stress in non-alcoholic steatohepatitis.

Authors:  G H Koek; P R Liedorp; A Bast
Journal:  Clin Chim Acta       Date:  2011-04-16       Impact factor: 3.786

Review 2.  Treatment of nonalcoholic fatty liver disease.

Authors:  Paul Angulo
Journal:  Ann Hepatol       Date:  2002 Jan-Mar       Impact factor: 2.400

3.  Some inflammatory cytokine levels, iron metabolism and oxidan stress markers in subjects with nonalcoholic steatohepatitis.

Authors:  Sema Uysal; Ferah Armutcu; Timucin Aydogan; Kayihan Akin; Mustafa Ikizek; M Ramazan Yigitoglu
Journal:  Clin Biochem       Date:  2011-10-08       Impact factor: 3.281

4.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

Review 5.  From the metabolic syndrome to NAFLD or vice versa?

Authors:  Ester Vanni; Elisabetta Bugianesi; Anna Kotronen; Samuele De Minicis; Hannele Yki-Järvinen; Gianluca Svegliati-Baroni
Journal:  Dig Liver Dis       Date:  2010-03-06       Impact factor: 4.088

6.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.

Authors:  Giulio Marchesini; Elisabetta Bugianesi; Gabriele Forlani; Fernanda Cerrelli; Marco Lenzi; Rita Manini; Stefania Natale; Ester Vanni; Nicola Villanova; Nazario Melchionda; Mario Rizzetto
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

7.  Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity.

Authors:  Piia Simonen; Anna Kotronen; Maarit Hallikainen; Ksenia Sevastianova; Janne Makkonen; Antti Hakkarainen; Nina Lundbom; Tatu A Miettinen; Helena Gylling; Hannele Yki-Järvinen
Journal:  J Hepatol       Date:  2010-08-22       Impact factor: 25.083

Review 8.  Interleukin-10 and chronic liver disease.

Authors:  Li-Juan Zhang; Xiao-Zhong Wang
Journal:  World J Gastroenterol       Date:  2006-03-21       Impact factor: 5.742

9.  Interleukin-10 to tumor necrosis factor-alpha ratio is a predictive biomarker in nonalcoholic fatty liver disease: interleukin-10 to tumor necrosis factor-alpha ratio in steatohepatitis.

Authors:  Reem M Hashem; Mona F Mahmoud; Mohamed A El-Moselhy; Hala M Soliman
Journal:  Eur J Gastroenterol Hepatol       Date:  2008-10       Impact factor: 2.566

10.  Non-alcoholic fatty liver disease (NAFLD)--the hepatic component of metabolic syndrome.

Authors:  Deepa Uchil; D Pipalia; M Chawla; R Patel; Sonali Maniar; Archana Juneja
Journal:  J Assoc Physicians India       Date:  2009-03
View more
  9 in total

1.  Severity of non-alcoholic fatty liver disease is associated with high systemic levels of tumor necrosis factor alpha and low serum interleukin 10 in morbidly obese patients.

Authors:  Gabriela Paredes-Turrubiarte; Antonio González-Chávez; Ruy Pérez-Tamayo; Beatriz Y Salazar-Vázquez; Vito S Hernández; Nayeli Garibay-Nieto; José Manuel Fragoso; Galileo Escobedo
Journal:  Clin Exp Med       Date:  2015-04-18       Impact factor: 3.984

2.  Misoprostol modulates cytokine expression through a cAMP pathway: Potential therapeutic implication for liver disease.

Authors:  Leila Gobejishvili; Smita Ghare; Rehan Khan; Alexander Cambon; David F Barker; Shirish Barve; Craig McClain; Daniell Hill
Journal:  Clin Immunol       Date:  2015-09-25       Impact factor: 3.969

3.  Changes in tumor necrosis factor-α, heat shock protein 70, malondialdehyde, and superoxide dismutase in patients with different severities of alcoholic fatty liver disease: a prospective observational study.

Authors:  Bao-Ge Qu; Hui Wang; Yi-Guo Jia; Ji-Liang Su; Zhong-Dong Wang; Ya-Fei Wang; Xing-Hai Han; Yuan-Xun Liu; Jin-Dun Pan; Guang-Ying Ren
Journal:  Medicine (Baltimore)       Date:  2015-03       Impact factor: 1.889

4.  Investigating Molecular Connections of Non-alcoholic Fatty Liver Disease with Associated Pathological Conditions in West Virginia for Biomarker Analysis.

Authors:  Dana L Sharma; Hari Vishal Lakhani; Rebecca L Klug; Brian Snoad; Rawan El-Hamdani; Joseph I Shapiro; Komal Sodhi
Journal:  J Clin Cell Immunol       Date:  2017-09-29

5.  Applications of Quantitative Systems Pharmacology (QSP) in Drug Development for NAFLD and NASH and Its Regulatory Application.

Authors:  Scott Q Siler
Journal:  Pharm Res       Date:  2022-05-24       Impact factor: 4.580

6.  Cytokines Genotype-Phenotype Correlation in Nonalcoholic Steatohepatitis.

Authors:  Ioana Corina Bocsan; Mircea Vasile Milaciu; Raluca Maria Pop; Stefan Cristian Vesa; Lorena Ciumarnean; Daniela Maria Matei; Anca Dana Buzoianu
Journal:  Oxid Med Cell Longev       Date:  2017-08-09       Impact factor: 6.543

7.  HbA1c may contribute to the development of non-alcoholic fatty liver disease even at normal-range levels.

Authors:  Changxi Chen; Zhongwei Zhu; Yushan Mao; Yimin Xu; Juan Du; Xiaoping Tang; Hongbao Cao
Journal:  Biosci Rep       Date:  2020-01-31       Impact factor: 3.840

8.  Prebiotic Xylo-Oligosaccharides Ameliorate High-Fat-Diet-Induced Hepatic Steatosis in Rats.

Authors:  Sanna Lensu; Raghunath Pariyani; Elina Mäkinen; Baoru Yang; Wisam Saleem; Eveliina Munukka; Maarit Lehti; Anastasiia Driuchina; Jere Lindén; Marja Tiirola; Leo Lahti; Satu Pekkala
Journal:  Nutrients       Date:  2020-10-22       Impact factor: 5.717

Review 9.  Abnormal metabolic processes involved in the pathogenesis of non-alcoholic fatty liver disease (Review).

Authors:  Mingmei Shao; Zixiang Ye; Yanhong Qin; Tao Wu
Journal:  Exp Ther Med       Date:  2020-08-28       Impact factor: 2.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.